Klin Monbl Augenheilkd 2016; 233(04): 488-489
DOI: 10.1055/s-0041-111805
Der interessante Fall
Georg Thieme Verlag KG Stuttgart · New York

Recurrent Central Serous Chorioretinopathy Under Combined Vemurafenib and Cobimetinib Treatment

Rezidiv einer Chorioretinopathia centralis serosa unter Behandlung mit Vemurafenib und Cobimetinib

Authors

  • P. Kouros

    1   Klinik Pallas, Olten, Switzerland (Director: Prof. Dr. Heinrich Gerding)
  • H. Gerding

    1   Klinik Pallas, Olten, Switzerland (Director: Prof. Dr. Heinrich Gerding)
    2   Department of Ophthalmology, University of Münster, Münster (Chairman: Prof. Dr. Nicole Eter)
Further Information

Publication History

Publication Date:
26 April 2016 (online)

Preview

Introduction

Mitogen-activated protein kinase (MAPK) inhibitor associated retinopathy (MAPK-retinopathy) resembling central serous chorioretinopathy (CSR) was described in few observational cohort-based studies [1], [2], [3] as well as in a case report [4]. Interestingly, the incidence of this complication seems to increase considerably under a combination of vemurafenib and cobimetinib as compared to vemurafenib monotherapy as was recently reported [2]. In this case symptoms of CSR started 3 days after introduction of vemurafenib and cobimetinib chemotherapy.